Table 1.
All Patients (n = 53) |
Urinary SARS-CoV-2 | p Value | Illness Severity | p Value | |||||
---|---|---|---|---|---|---|---|---|---|
URNA− (n = 38, 71.7%) |
URNA+ (n = 15, 28.3%) |
URNA− vs. URNA+ |
Non-Severe | Severe | S URNA+ vs. S URNA− |
||||
URNA− (n = 26, 86.7%) |
URNA+ (n = 4, 13.3%) |
URNA− (n = 12, 52.2%) |
URNA+ (n = 11, 47.8%) |
||||||
Demographic characteristic (No., %) | |||||||||
Age, years | 52 (42.0–66.0) |
51.0 (38.3–59.8) |
61.0 (48.5–72.0) |
0.016 | 50.5 (37.3–56.8) |
50.0 (48.5–60.8) |
55.0 (51.0–63.5) |
66.0 (50.0–72.0) |
0.126 |
Female | 31/53 (58%) | 22/38 (58%) | 9/15 (60%) | 0.889 | 17/26 (65%) | 3/4 (75%) | 5/12 (42%) | 6/11 (55%) | 0.684 |
Respiratory symptoms (No., %) | |||||||||
Fever | 41/53 (77.4%) | 31/38 (73.7%) | 13/15 (86.7%) | 0.969 | 16/26 (61.5%) | 4/4 (100.0%) | 12/12 (100.0%) | 9/11 (81.8%) | 0.217 |
Cough | 38/53 (71.7%) | 31/38 (73.7%) | 10/15 (66.7%) | 0.421 | 19/26 (73.1%) | 3/4 (75.0%) | 9/12 (75.0%) | 7/11 (63.6%) | 0.667 |
Sputum production | 13/53 (24.5%) | 9/38 (23.7%) | 6/15 (40.0%) | 0.396 | 5/26 (19.2%) | 3/4 (75.0%) | 2/12 (16.7%) | 3/11 (27.3%) | 0.640 |
Fatigue | 18/53 (34.0%) | 11/38 (29.0%) | 7/15 (46.7%) | 0.220 | 9/26 (34.6%) | 3/4 (75.0%) | 2/12 (16.7%) | 4/11 (36.4%) | 0.371 |
Chest tightness | 14/53 (26.4%) | 6/38 (15.8%) | 9/15 (60.0%) | 0.001 | 3/26 (11.5%) | 3/4 (75.0%) | 2/12 (16.7%) | 6/11 (54.6%) | 0.089 |
Shortness of breath | 19/53 (35.9%) | 12/38 (31.6%) | 10/15 (66.7%) | 0.02 | 0/26 (0.0%) | 0/4 (0.0%) | 9/12 (75.0%) | 10/11 (90.9%) | 0.590 |
Radiological appearance (No., %) | |||||||||
Unilateral pneumonia | 2/53 (3.77%) | 2/38 (5.3%) | 0/15 (0.0%) | 0.365 | 2/26 (7.7%) | 0/4 (0.0%) | 0/12 (0.0%) | 0/11 (0.0%) | UTC |
Bilateral pneumonia | 35/53 (66.0%) | 26/38 (68.4%) | 9/15 (60.0%) | 0.560 | 17/26 (62.4%) | 1/4 (25.0%) | 9/12 (75.0%) | 8/11 (72.7%) | 1.000 |
Multiple “ground-glass opacity” lesions | 20/35 (37.7%) | 17/38 (44.7%) | 3/15 (20.0%) | 0.094 | 14/26 (53.9%) | 0/4 (0.0%) | 3/12 (25.0%) | 3/11 (27.3%) | 1 |
Comorbidities (No., %) | |||||||||
Hypertension | 19/53 (35.9%) | 11/38 (29.0%) | 8/15 (53.3%) | 0.095 | 9/26 (34.6%) | 0/4 (0.0%) | 2/12 (16.7%) | 8/11 (72.7%) | 0.012 |
Diabetes | 7/53 (13.2%) | 5/38 (13.2%) | 2/15 (13.3%) | 0.986 | 3/26 (11.5%) | 0/4 (0.0%) | 2/12 (16.7%) | 2/11 (18.2%) | 1.000 |
Cardiovascular diseases | 6/53 (11.3%) | 2/38 (5.3%) | 4/15 (26.7%) | 0.083 | 2/26 (7.7%) | 0/4 (0.0%) | 0/12 (0.0%) | 4/11 (36.4%) | 0.037 |
Chronic renal disease | 2/53 (3.8%) | 2/38 (5.3%) | 0/15 (0.0%) | 0.365 | 2/26 (7.7%) | 0/4 (0.0%) | 0/12 (0.0%) | 0/11 (0.0%) | UTC |
In-hospital death (No., %) | 6/53 (11.3%) | 2/38 (5.3%) | 4/15 (26.7%) | 0.083 | 0/26 (0.0%) | 0/4 (0.0%) | 2/12 (16.7%) | 4/11 (36.4%) | 0.371 |
Data shown as medians (interquartile ranges, IQR) and numbers/total (%); UTC, unable to calculate; URNA−, negative urinary SARS-CoV-2; URNA+, positive urinary SARS-CoV-2; S, Severe. p values presented the comparison between Negative cases and positive cases. p < 0.05 was considered statistically significant.